Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$65.24

-0.31 (-0.47%)

10:43
10/14/16
10/14
10:43
10/14/16
10:43

Battleground: Analysts diverge on bluebird bio after investor day

Shares of bluebird bio (BLUE) are sliding after Cantor Fitzgerald analyst Elemer Piros downgraded the stock to Sell, citing a lack of catalysts in the near-term as he thinks initial data on improved transduction efficiency in beta-thalassemia and severe sickle cell disease may not become available until 2018. Conversely, his peers at Leerink and SunTrust remain bullish on bluebird bio and the company's outlook. LACK OF CATALYSTS: After attending bluebird's analyst and investor meeting yesterday, October 13, Cantor Fitzgerald's Piros downgraded bluebird bio to Sell from Hold citing a lack of upcoming catalysts, as he does not expect any new data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. While bluebird bio disclosed that all future LentiGlobin trials in transfusion-dependent beta-thalassemia and severe sickle cell disease going forward will use its improved manufacturing process, Piros noted that initial data may not become available until 2018 since those trials are just beginning. Further, the analyst told investors that the lack of catalysts for some time should likely lead to selling pressure on the company's shares. He lowered his price target on the stock to $37 from $42. CLINICAL DEVELOPMENT, REGULATORY PATH DE-RISKED: Conversely, Leerink analyst Michael Schmidt remains bullish on bluebird bio, raising his price target on the shares to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. Additionally, Schmidt told investors that he expects updates from ongoing LentiGlobin trials at the upcoming ASH conference. He reiterated an Outperform rating on the shares. IMPROVED OUTLOOK: In a note of his own, SunTrust analyst Edward Nash was also upbeat on bluebird bio, saying that a higher transduction efficiency in LentiGlobin should lead to improved clinical benefit and, therefore, allow the company to target the entire transfusion-dependent B-thalassemia population. Moreover, additional protocol amendments for sickle cell disease will likely have a positive impact on the clinical outcome, Nash added. He also pointed out that he believes bluebird bio is on track in pursuing FDA and EMA approvals for LentiGlobin. The analyst reiterated a Buy rating and $115 price target on the shares. PRICE ACTION: In morning trading, shares of bluebird bio have dropped 6% to $61.31.

  • 06

    Nov

  • 29

    Nov

BLUE bluebird bio
$65.24

-0.31 (-0.47%)

10/14/16
CANT
10/14/16
DOWNGRADE
Target $37
CANT
Sell
Cantor cuts bluebird bio to Sell with $37 price target
Cantor Fitzgerald analyst Elemer Piros downgraded bluebird bio to Sell from Hold and dropped his price target for the shares to $37 from $42. The biotech focused on developing gene therapies closed yesterday down 31c to $64.24. The analyst sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. Bluebird disclosed yesterday that all future LentiGlobin trials going forward will use its improved manufacturing process, and those trials are just beginning, Piros tells investors in a research note. As such, initial data on improved transduction efficiency may not become available until 2018, the analyst contends. With this year's ASH meeting not a catalyst, Piros expects selling pressure on bluebird shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $80
LEER
Outperform
bluebird bio price target raised to $80 from $67 at Leerink
Leerink analyst Michael Schmidt raised his price target for bluebird bio to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. He reiterates an Outperform rating on the shares.
10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
bluebird bio outlook has improved, says SunTrust
SunTrust analyst Edward Nash believes that the improvement in the transduction efficiency of bluebird's LentiGlobin should enable the company "to target the entire transfusion-dependent B-thalassemia population" for the first time. Nash adds that the changes should also improve LentiGlobin's efficacy in sickle cell. He reiterates a $115 price target and Buy rating on the stock.
10/14/16
10/14/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Sell from Hold at Canaccord with the firm citing the gap between the average free cash flow generation of Shell over the past two decades and the medium-term target. 2. bluebird bio (BLUE) downgraded to Sell from Hold at Cantor with analyst Elemer Piros saying he sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. 3. Fluor (FLR) downgraded to Neutral from Accumulate at Seaport Global with analyst Ryan Cassil citing persistently weaker global macroeconomic trends and expectations for a continuation of weaker project activity in 2017. 4. Boston Beer (SAM) downgraded to Hold from Buy at Berenberg. 5. Estee Lauder (EL) downgraded to Neutral from Overweight at Piper Jaffray after the firm's semi-annual proprietary "Taking Stock With Teens" survey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AUDC

AudioCodes

$6.62

0.11 (1.69%)

05:51
04/26/17
04/26
05:51
04/26/17
05:51
Earnings
AudioCodes reports Q1 EPS 7c, consensus 7c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$24.82

0.07 (0.28%)

05:51
04/26/17
04/26
05:51
04/26/17
05:51
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BIG

Big Lots

$49.57

-0.36 (-0.72%)

05:49
04/26/17
04/26
05:49
04/26/17
05:49
Upgrade
Big Lots rating change  »

Big Lots upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTI

Apptio

$12.80

0.09 (0.71%)

05:48
04/26/17
04/26
05:48
04/26/17
05:48
Upgrade
Apptio rating change  »

Apptio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

NORD

Nord Anglia

$32.82

5.2 (18.83%)

05:46
04/26/17
04/26
05:46
04/26/17
05:46
Downgrade
Nord Anglia rating change  »

Nord Anglia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

AKS

AK Steel

$6.40

-0.72 (-10.11%)

05:44
04/26/17
04/26
05:44
04/26/17
05:44
Recommendations
AK Steel analyst commentary  »

AK Steel selloff a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

CMG

Chipotle

$471.76

2.97 (0.63%)

05:43
04/26/17
04/26
05:43
04/26/17
05:43
Downgrade
Chipotle rating change  »

Chipotle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$76.65

0.82 (1.08%)

05:43
04/26/17
04/26
05:43
04/26/17
05:43
Downgrade
Shopify rating change  »

Shopify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 24

    May

ALGT

Allegiant Travel

$163.85

-1.2 (-0.73%)

05:40
04/26/17
04/26
05:40
04/26/17
05:40
Downgrade
Allegiant Travel rating change  »

Allegiant Travel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DYN

Dynegy

$6.19

-0.11 (-1.75%)

05:37
04/26/17
04/26
05:37
04/26/17
05:37
Upgrade
Dynegy rating change  »

Dynegy upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

RSPP

RSP Permian

$38.69

1.32 (3.53%)

05:33
04/26/17
04/26
05:33
04/26/17
05:33
Initiation
RSP Permian initiated  »

RSP Permian reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CPE

Callon Petroleum

$12.24

0.39 (3.29%)

05:32
04/26/17
04/26
05:32
04/26/17
05:32
Initiation
Callon Petroleum initiated  »

Callon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

LOGI

Logitech

$31.79

0.99 (3.21%)

05:32
04/26/17
04/26
05:32
04/26/17
05:32
Earnings
Logitech backs FY18 outlook of high single-digit retail sales growth »

Logitech confirmed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FSNN

Fusion Telecommunications

$1.43

0.01 (0.70%)

05:31
04/26/17
04/26
05:31
04/26/17
05:31
Initiation
Fusion Telecommunications initiated  »

Fusion Telecommunications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

LOGI

Logitech

$31.79

0.99 (3.21%)

05:30
04/26/17
04/26
05:30
04/26/17
05:30
Earnings
Logitech reports Q4 EPS 15c, consensus 17c »

Reports Q4 revenue $496M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SKYAY

Sky

$50.26

0.05 (0.10%)

05:29
04/26/17
04/26
05:29
04/26/17
05:29
Upgrade
Sky rating change  »

Sky upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.56

0.91 (1.70%)

05:26
04/26/17
04/26
05:26
04/26/17
05:26
Hot Stocks
Wells Fargo issues statement in response to CA State Treasurer John Chiang »

"Notwithstanding the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

KLRE

KLR Energy Acquisition

$10.55

0.1384 (1.33%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Ionis Pharmaceuticals management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 24

    May

ADMS

Adamas Pharmaceuticals

$16.36

0.51 (3.22%)

, AVXS

AveXis

$78.74

-0.44 (-0.56%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
American Academy of Neurology »

69th Annual Meeting of…

ADMS

Adamas Pharmaceuticals

$16.36

0.51 (3.22%)

AVXS

AveXis

$78.74

-0.44 (-0.56%)

CATB

Catabasis Pharmaceuticals

$1.48

-0.02 (-1.33%)

MNOV

MediciNova

$5.57

0.14 (2.58%)

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

FLKS

Flex Pharma

$3.07

0.01 (0.33%)

TGTX

TG Therapeutics

$12.00

1.6 (15.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 24

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 24

    Aug

ATEC

Alphatec

$1.98

0.02 (1.02%)

, CAE

CAE

$15.39

0.01 (0.07%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
American Association of Neurological Surgeons to hold annual meeting »

2017 AANS Annual…

ATEC

Alphatec

$1.98

0.02 (1.02%)

CAE

CAE

$15.39

0.01 (0.07%)

EDGE

Edge Therapeutics

$10.72

1.07 (11.09%)

MDT

Medtronic

$81.76

1.11 (1.38%)

NUVA

NuVasive

$76.94

0.59 (0.77%)

SYK

Stryker

$135.59

1.14 (0.85%)

VRTX

Vertex

$117.27

-0.39 (-0.33%)

SYNA

Synaptics

$52.54

0.84 (1.62%)

NVIV

InVivo Therapeutics

$4.00

0.05 (1.27%)

LMAT

LeMaitre

$25.63

0.17 (0.67%)

MZOR

Mazor Robotics

$34.74

0.98 (2.90%)

OFIX

Orthofix

$39.28

0.19 (0.49%)

SSNLF

Samsung

SIEGY

Siemens

$72.70

0.615 (0.85%)

SNE

Sony

$33.65

-0.17 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 18

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 06

    Jun

ABUS

Arbutus Biopharma

$3.35

0.05 (1.52%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Arbutus Biopharma management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SXL

Sunoco Logistics

$24.35

0.64 (2.70%)

, ETP

Energy Transfer Partners

$36.42

0.98 (2.77%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Energy Transfer Partners to host special shareholder meeting »

Special Shareholder…

SXL

Sunoco Logistics

$24.35

0.64 (2.70%)

ETP

Energy Transfer Partners

$36.42

0.98 (2.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    May

TIG

TiGenix

$16.36

0.08 (0.49%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
TiGenix management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

MTSI

MACOM

$53.84

-0.17 (-0.31%)

, SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$53.84

-0.17 (-0.31%)

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

NXST

Nexstar

$68.90

0.3 (0.44%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.